Table 4.

Prevalence, antibiotic resistance, and outcomes of SBP subgroup by income level.

	Middle income group				Higher income group
	Papers	Sample	Events	Pooled proportion	Papers	Sample	Events	Pooled proportion	Relative risk	95% CI	p-value
Prevalence	27	7,441	1,366	20.27% (14.89–26.97%)	45	5,709,793	136,936	15.44% (11.29–20.75%)	1.31	1.25–1.37	<0.01
Antibiotic resistance	5	1,334	200	12.65% (7.82–19.81%)	16	1,929	238	11.63% (6.67–19.52%)	1.09	0.90–1.31	0.385
Mortality	11	1,422	434	30.15% (19.39–43.64%)	15	3,331	1,027	30.96% (21.62–42.16%)	0.97	0.89–1.07	0.59
In hospital mortality	4	434	174	22.69% (4.12–66.73%)	10	16,603	3,766	23.47% (16.57–32.15%)	0.97	0.81–1.15	0.72
30-day mortality	4	1,076	269	25.72% (21.65–30.26%)	9	2,645	638	25.58% (21.33–30.36%)	1.01	0.89–1.15	0.94
90-day mortality	1	55	21	38.18% (26.39–51.55%)	7	2,460	949	37.61% (30.95–44.79%)	1.02	0.72–1.43	0.94
AKI	3	355	689	59.68% (33.19–81.52%)	2	115,518	44,117	38.19% (37.91–38.47%)	1.56	1.47–1.66	<0.01